계명대학교 의학도서관 Repository

A Multi-Center, Phase II Clinical T rial of PadexolTM (Paclitaxel) and Cisplatin for Patients Suffering w ith A dvanced Gastric Cancer

Metadata Downloads
Author(s)
도영록송홍석박건욱
Alternative Author(s)
Do, Young RokSong, Hong SukPark, Keon Uk
Publication Year
2005
Abstract
Purpose : We conducted a multi-center, phase II trial to evaluate the efficacy and safety of using Padexol (a paclitaxel formulation) combined with cisplatin for the patients suffering with advanced gastric adenocarcinoma.
Materials and Methods : 39 patients (median age: 60 years; males: 90%) who were diagnosed with advanced gastric cancer were enrolled from 5 hospitals. Padexol 175 mg/m2 was administered as a 3-hr infusion, and this was followed by cisplatin 75 mg/m2 as an intravenous infusion on day 1, once every 3 weeks.
Results : Out of these 39 patients, 34 patients were assessable for treatment efficacy and 39 patients were assessable for the toxicity. Objective responses occurred in 13 patients (33%); 1 patient (3%) had a complete response and 12 patients (31%) had partial responses. 6 patients (15%) achieved a stable disease state. The median duration of response was 7.1 months, and the median time to progression and the overall survival were 4.8 months and 6.7 months, respectively. The major treatment-related adverse events were hematologic toxicity, including WHO grade 3 or 4 neutropenia in 13 patients (33%). However, febrile neutropenia occurred in only 1 patient and the non-hematologic toxicity was usually mild.
Conclusion : The combination of Padexol and cisplatin was found to be active and it seems to be a relatively well-tolerated regimen for the treatment of advanced gastric cancer.
Key words: Padexol™, Paclitaxel, Cisplatin, Stomach neoplasms
Department
Dept. of Internal Medicine (내과학)
Publisher
School of Medicine
Citation
Cancer Research and Treatment, Vol.37(6) : 349-353, 2005
Type
Article
ISSN
1598-2998
DOI
10.4143/crt.2005.37.6.349
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/35339
Authorize & License
  • AuthorizeOpen
Files in This Item:

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.